Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial

MLA

Véronique Quillien, et al. Validation of the High-Performance of Pyrosequencing for Clinical MGMT Testing on a Cohort of Glioblastoma Patients from a Prospective Dedicated Multicentric Trial. Aug. 2016. EBSCOhost, https://doi.org/10.18632/oncotarget.11322⟩.

APA

Véronique Quillien, Olivier Chinot, Dominique Figarella-Branger, Guenaelle Levallet, Michèle Legrain, Marie-Odile Joly, Pierre Rivet, Emmanuèle Lechapt Zalcman, François Ducray, Marc Sanson, Audrey Lavenu, Fabienne Escande, Catherine Carpentier, Natacha Entz-Werle, Lucie Karayan-Tapon, Dan Cristian Chiforeanu, Frédéric Fina, Carole Ramirez, & Elodie Vauleon. (2016). Validation of the high-performance of pyrosequencing for clinical MGMT testing on a cohort of glioblastoma patients from a prospective dedicated multicentric trial. https://doi.org/10.18632/oncotarget.11322⟩

Chicago

Véronique Quillien, Olivier Chinot, Dominique Figarella-Branger, Guenaelle Levallet, Michèle Legrain, Marie-Odile Joly, Pierre Rivet, et al. 2016. “Validation of the High-Performance of Pyrosequencing for Clinical MGMT Testing on a Cohort of Glioblastoma Patients from a Prospective Dedicated Multicentric Trial,” August. doi:10.18632/oncotarget.11322⟩.